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ABSTRACT
In the completed phase I trial NCT01450384 combining the anti-folate pemetrexed 
and the multi-kinase inhibitor sorafenib it was observed that 20 of 33 patients had 
prolonged stable disease or tumor regression, with one complete response and 
multiple partial responses. The pre-clinical studies in this manuscript were designed to 
determine whether [pemetrexed + sorafenib] –induced cell killing could be rationally 
enhanced by additional signaling modulators. Multiplex assays performed on tumor 
material that survived and re-grew after [pemetrexed + sorafenib] exposure showed 
increased phosphorylation of ERBB1 and of NFκB and IκB; with reduced IκB and 
elevated G-CSF and KC protein levels. Inhibition of JAK1/2 downstream of the G-CSF/
KC receptors did not enhance [pemetrexed + sorafenib] lethality whereas inhibition 
of ERBB1/2/4 using kinase inhibitory agents or siRNA knock down of ERBB1/2/3 
strongly promoted killing. Inhibition of ERBB1/2/4 blocked [pemetrexed + sorafenib] 
stimulated NFκB activation and SOD2 expression; and expression of IκB S32A S36A 
significantly enhanced [pemetrexed + sorafenib] lethality. Sorafenib inhibited HSP90 
and HSP70 chaperone ATPase activities and reduced the interactions of chaperones 
with clients including c-MYC, CDC37 and MCL-1. In vivo, a 5 day transient exposure 
of established mammary tumors to lapatinib or vandetanib significantly enhanced the 
anti-tumor effect of [pemetrexed + sorafenib], without any apparent normal tissue 
toxicities. Identical data to that in breast cancer were obtained in NSCLC tumors using 
the ERBB1/2/4 inhibitor afatinib. Our data argue that the combination of pemetrexed, 
sorafenib and an ERBB1/2/4 inhibitor should be explored in a new phase I trial in 
solid tumor patients.
INTRODUCTION
The anti-folate drug pemetrexed (abbreviated in 
this manuscript as “PTX”) (Alimta®) was FDA-approved 
for the treatment of advanced and metastatic non-small 
cell lung cancer (NSCLC) in 2004. Pemetrexed was 
developed as an inhibitor of thymidylate synthase (TS), 
however based on its continued anti-proliferative effect 
on cells in vitro in the presence of exogenous thymidine, 
preventing the cytotoxic effects of TS inhibition, it became 
apparent that pemetrexed has at least one secondary 
target [1-4]. Subsequently, the folate-dependent enzyme, 
aminoimidazole-carboxamide ribonucleotide formyl-
transferase (AICART), was shown to be a secondary 
target for pemetrexed [1, 2]. Inhibition of AICART 
increases ZMP levels, and elevated [ZMP] causes 
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activation of AMP-activated protein kinase (AMPK) 
and downstream inhibition of mammalian target of 
rapamycin (mTOR) and activation of ULK-1 [1, 2, 5]. 
Inhibition of mTOR and activation of ULK-1 stimulates 
autophagy in part by reducing phosphorylation of ULK1 
Serine 757 and by increasing phosphorylation of ULK-1 
S317; thus activating the ULK-1 kinase to phosphorylate 
ATG13 S318, and enabling the association of additional 
ATG proteins required to initiate formation of the 
autophagosome [6-10]. 
Sorafenib and regorafenib are multi-kinase 
inhibitors approved for the treatment of liver and kidney, 
and colon cancers, respectively [11, and references 
therein]. Sorafenib was originally developed as an 
inhibitor of RAF-1 in the ERK1/2 pathway. The steady 
state (7 day) Cmax for sorafenib is ~21 µM in plasma, with 
~99% of the drug protein bound based on in vitro human 
serum binding assays; though it is known that the drug is 
also rapidly taken up into tissues, and in addition patient 
data from clinical trials would argue that a significant 
amount of the drug has to be bioavailable, at least in the 
low micro-molar range, in a tumor based on its single 
agent effects by decreasing both ERK1/2 phosphorylation 
and reducing MCL-1 protein expression in tumor cells that 
are not specifically oncogene addicted [12, 13]. Indeed, it 
has been shown that some sorafenib metabolites such as 
M2, M4 and M5 can have up to 10-fold greater activity 
than the parent drug [14-16]. Our prior data have tended 
to argue using several sorafenib + drug combinations that 
PDGFRβ is a major target of sorafenib for its interactions 
with other agents e.g. with histone deacetylase inhibitors 
[12, 13]. 
A major biological effect of sorafenib is the 
induction of an endoplasmic stress (ER) / unfolded protein 
response (UPR), with reduced expression of proteins that 
have short half-lives such as MCL-1 and BCL-XL [17, 
18]. Reduced MCL-1 levels due to sorafenib exposure 
have been linked in many tumor types to increased levels 
of apoptosis. Studies by our group have also linked high 
dose single agent sorafenib exposure to an increase in 
the levels of autophagic markers including increased 
numbers of LC3-GFP intense staining vesicles and 
elevated expression of Beclin1 and ATG5; lower sorafenib 
concentrations only caused a modest transient alteration 
in autophagy flux [12, 13]. Other studies from our groups 
have shown that based on the sorafenib dose the induction 
of ER stress may be a “protective” or a “toxic” event in the 
cellular response to the drug [e.g. 19].
We recently reported at the 2015 ASCO meeting 
data from a completed phase I trial to determine the 
maximum safe doses of [pemetrexed + sorafenib] that can 
be administered to a heavily pre-treated cancer patient 
population (NCT01450384) [20]. A new phase II study 
specifically in HER2 negative ER/PR negative breast 
cancer has opened at Massey Cancer Center in the winter 
of 2016 (NCT02624700). Based on the early preliminary 
NCT01450384 phase I trial findings in 2014, the present 
pre-clinical studies were initiated to define in a rational 
manner the most efficacious “third agent” that could 
enhance [pemetrexed + sorafenib] lethality.
RESULTS AND DISCUSSION
As reported at the 2015 ASCO meeting, treatment 
of heavily pre-treated recurrent solid tumor patients with 
[pemetrexed + sorafenib] resulted in ~60% of all patients 
experiencing some degree of tumor growth delay (SD, PR, 
CR), with multiple partial responses and one complete 
response (Figure 1A; NCT01450384) [20]. 
As the two drug combination of [pemetrexed + 
sorafenib] effectively killed tumor cells in vitro, in vivo 
and in patients, we next searched for an efficacious 
translatable third drug which could be used to further 
enhance [pemetrexed + sorafenib] lethality. Multiple 
prior studies using sorafenib in the Dent laboratory have 
demonstrated that it synergizes with histone deacetylase 
inhibitors to kill tumor cells [12, 13]. Furthermore, 
data from our on-going phase I trial in hepatocellular 
carcinoma combining sorafenib and vorinostat has shown 
that multiple patients have displayed prolonged > 6 
months stable disease (NCT01075113) (Poklepovic and 
Dent, unpublished observations). In the “triple negative” 
mouse mammary tumor cell line 4T1 [pemetrexed + 
sorafenib] interacted to kill, an effect that was enhanced 
by the histone deacetylase inhibitor and also inhibitor of 
sphingosine-1-phosphate signaling FTY720 (Fingolimod, 
Gilenya®) (Figure 1B). The ability of other clinically 
relevant histone deacetylase inhibitor drugs to enhance 
[pemetrexed + sorafenib] toxicity was also examined, and 
it was noted that the class I / class II histone deacetylase 
inhibitors vorinostat and AR-42 both strongly and more 
rapidly enhanced [sorafenib + pemetrexed] lethality 
than FTY720 (Figures 1B and 1C). Transient treatment 
of animals with low doses of [pemetrexed + sorafenib] 
modestly reduced the growth of established orthotopic 4T1 
mouse mammary tumors in their syngeneic host BALB/c 
mouse (Figure 1D). Combined treatment of animals with 
[sorafenib + pemetrexed + AR-42] significantly reduced 
tumor growth below that of [pemetrexed + sorafenib] 
alone and enhanced animal survival using this highly 
aggressive ERBB1 expressing triple negative mammary 
carcinoma (p < 0.05).
In parallel studies with the animals being exposed 
to drugs for 5 days and animals humanely sacrificed at 
day 7, mouse blood and tumors were analyzed for mouse 
cytokine levels with and without drug treatments using a 
Bio-Rad MAGPIX multiplex system and antibody micro-
arrays (Figures 2A-2D). We noted that the expression 
of G-CSF was increased by [pemetrexed + sorafenib] 
treatment, which was reduced by AR-42. Basal expression 
of IL-12 (p40) and of KC (CXCL1) was high, that was 
reduced by AR-42 treatment. Similar findings were also 
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obtained, albeit with lower cytokine levels, examining 
IL-6, IL-9, IL-10 and IFN-γ. [Pemetrexed + sorafenib] 
treatment increased the phosphorylation of ERBB1, 
which was reduced by AR-42 (Figure 2B). Similar more 
modest findings were noted for PDGFRα/β. This reduction 
in ERBB1 phosphorylation by co-exposure with AR-42 
correlated with reduced phosphorylation of ERK1/2, AKT, 
p70 S6K and mTOR, which was also associated with 
reduced S6 phosphorylation (Figure 2C). Downstream 
of the membrane-to-nucleus signaling pathways, AR-
42 reduced the levels of c-Jun phosphorylation and both 
[pemetrexed + sorafenib] as well as AR-42 increased 
the phosphorylation of the NFκB p65 subunit but when 
combined as [pemetrexed + sorafenib + AR-42] decreased 
NFκB p65 phosphorylation (Figure 2D). Collectively, 
the data in Figures 1 and 2 argues that the combination 
of [pemetrexed + sorafenib] with clinically relevant 
HDAC inhibitors represents a promising approach for the 
treatment of triple negative breast cancer.
Based on the findings in Figure 2 and the identified 
molecular response biomarkers, we determined whether 
an inhibitor of KC and G-CSF signaling (i.e. the clinically 
Figure 1: [Pemetrexed and Sorafenib] interact with modulators of bioactive lipid metabolism and with histone 
deacetylase inhibitors to kill tumor cells. A. A phase I trial was performed combining pemetrexed and sorafenib at increasing doses 
(3 x 3 standard design). (see the companion Poklepovic et al manuscript, ref. 20). The data presented are from two patients on the trial: a 
thymic carcinoma patient and an ER+/PR+/HER2+ mammary carcinoma patient (see Methods of approach in reference 20 for additional 
details). B. BT474 human mammary carcinoma cells were treated with [pemetrexed (PTX, 0.5 µM) and sorafenib (2.0 µM)] in the presence 
or absence of the histone deacetylase inhibitors: FTY720 (0.1 µM); Vorinostat (0.5 µM); AR-42 (0.5 µM). Cells were examined 3-24h after 
treatment using a live / dead viability stain where green cells are viable and yellow / red cells are dead in WiScan Hermes instrument. C. 
4T1 mouse mammary carcinoma cells were treated with [pemetrexed (PTX, 0.5 µM) and sorafenib (2.0 µM)] in the presence or absence 
of the histone deacetylase inhibitors: FTY720 (0.1 µM); Vorinostat (0.5 µM); AR-42 (0.5 µM). Cells were examined 3-24h after treatment 
using a live / dead viability stain where green cells are viable and yellow / red cells are dead in WiScan Hermes instrument. D. 4T1 cells 
(20,000) were injected into a BALB/c immune competent mouse fourth mammary fat pad. Five days after injection animals were randomly 
segregated into four groups. Animals were treated with vehicle (cremophore), [sorafenib (10 mg/kg) + pemetrexed (25 mg/kg)], AR-42 (10 
mg/kg) or all three drugs simultaneously for 5 days QD. Please note the low level of sorafenib dosing in this specific animal study. Tumor 
volume was measured at Day 0 (no tumors evident) and then again beginning at Day 8 and then every seventh day and the actual increase 
in tumor volume calculated (2 studies, 8 animals total per group +/- SEM) *p < 0.05 lower than [sorafenib + pemetrexed] alone value.
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relevant JAK1/2 inhibitor ruxolitinib), or an inhibitor of 
ERBB1/2/4 signaling (i.e. the clinically relevant inhibitor 
lapatinib) could modify the toxicity of [pemetrexed 
+ sorafenib] in 4T1 and in BT474 cells. In 4T1 cells 
inhibition of ERBB1/2/4 signaling by use of lapatinib, 
but not inhibition of JAK1/2 signaling using ruxolitinib, 
enhanced [pemetrexed + sorafenib] lethality (Figure 3A, 
upper). Similar data were obtained in BT474 cells using 
the ERBB1/2/4 inhibitors afatinib, vandetanib, the recently 
approved 3rd generation inhibitor AZD9291, sapitinib, 
poziotinib and neratinib, but not with either of the ERBB1 
only specific inhibitor drugs gefitinib or erlotinib (Figure 
3A, middle/lower panels). 
The drugs afatinib and pemetrexed are approved 
for use in non-small cell lung cancer patients and 
we next determined the killing abilities of sorafenib, 
pemetrexed and afatinib in NSCLC cell lines. Sorafenib 
and pemetrexed interacted to kill with varying efficacies 
all of NSCLC lines tested; an effect that was enhanced by 
afatinib, regardless of whether the cell line expressed a 
mutant active ERBB1 or a mutant active N-RAS / K-RAS 
or lacked p16 / p53 function (Figure 3B). Molecular 
knock down of ERBB receptors recapitulated the effects 
caused by ERBB1/2/4 inhibitors in SUM149 and BT474 
breast cancer cells with combined knock down of ERBB2 
and ERBB3 facilitating strong killing in SUM149 cells 
and with combined knock down of ERBB1 and ERBB2 
facilitating strong killing in BT474 cells (Figure 3C).
Pemetrexed causes DNA damage and we next 
investigated the role of NFκB and ATM / DNA repair 
in survival signaling in vitro (Figure 4). [Pemetrexed + 
sorafenib] treatment not only resulted in surviving cells 
having increased phosphorylation of p65 NFκB but also 
with decreased total expression of IκB and increased 
Figure 2: Multiplex data on plasma cytokine levels and tumor signal transduction protein phosphorylation after 7 days 
of mouse drug treatment. A.-D. Animals carrying 4T1 tumors, five days after injection, were subjected to drug treatment for 5 days as 
per Figure 1D. After seven days, animals were sacrificed and blood and tumor obtained. Clarified plasma and tumor cell lysates were then 
subjected to multiplex assays as described in the Methods to detect the plasma levels of the indicated cytokines and phosphorylation status 
of signal transduction proteins using a Bio-Rad MAGPIX multiplex instrument (total 8 animals per condition, +/- SEM). In Panels A-D the 
data are grouped in sets of four bars for each protein assessment, in order: vehicle treatment; [PTX+SOR] treatment; AR-42 treatment; 
[PTX+SOR] + AR-42 treatment. # p < 0.05 less than vehicle control value; * p < 0.05 less than corresponding value without AR-42.
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Figure 3: Inhibition of ERBB1/2 but not JAK1/2 significantly enhances tumor cell killing by [Pemetrexed and 
Sorafenib]. A. BT474 and 4T1 cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], ruxolitinib (0.5 µM), 
lapatinib (1 µM), afatinib (0.5 µM), neratinib (0.5 µM), ZD6474/Vandetanib (0.2 µM), sapitinib (0.2 µM), poziotinib (0.2 µM), AZD9291 
(0.2 µM) or the drugs in combination as indicated. After 12h of incubation, cells were treated with live / dead reagent and cells examined 
using a Hermes WiScan microscope where red/yellow cells = dead; green cells = alive (n = 3 +/- SEM). * p < 0.05 greater than [PTX+SOR] 
treatment alone. B. NSCLC lines were treated with vehicle control, pemetrexed (0.5 µM) and/or sorafenib (2 µM) for 24h after which 
cell viability was determined by live/dead assay (+/- SEM) *p < 0.05 greater than pemetrexed alone value). In parallel studies NSCLC 
lines were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], afatinib (0.5 µM), lapatinib (1.0 µM) or the drugs in 
combination. Twelve h after treatment cell viability was determined by live/dead assay (+/- SEM) ¶ p < 0.05 greater than corresponding 
24h value of [pemetrexed + sorafenib] only. C. BT474 and SUM149 human mammary carcinoma cells were transfected with a scrambled 
siRNA (siSCR) or to knock down the expression of ERBB1, ERBB2, ERBB3, ERBB4 in the combinations indicated in the Figure. Twenty 
four h after transfection cells were treated with vehicle control or with [pemetrexed (0.5 µM) and sorafenib (2 µM)] as indicated. After 12h 
of incubation, cells were treated with live / dead reagent and cells examined using a Hermes WiScan microscope where red/yellow cells = 
dead; green cells = alive (+/- SEM) * p < 0.05 greater than P+S value in siSCR transfected cells; $ p < 0.05 greater than the other receptor 
combination values.
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the mole/mole phosphate ratio in IκB in tumor cells 
isolated after animal treatment (Figure 4A). As judged 
by immuno-fluorescent in situ staining, treatment of 
BT474 and SUM149 cells in vitro with [pemetrexed + 
sorafenib] increased the phosphorylation of p65 NFκB 
S536, indicative of increased transcriptional activity 
(Figure 4B). Lapatinib did not significantly alter basal 
p65 phosphorylation but abolished stimulated p65 
phosphorylation when combined with [pemetrexed + 
sorafenib]. Mn Cu superoxide dismutase 2 (SOD2) is one 
well-recognized cyto-protective NFκB target gene and in 
agreement with our p65 phosphorylation data, lapatinib 
prevented [pemetrexed + sorafenib] -induced SOD2 
expression. Our drug treatments that included pemetrexed 
Figure 4: Inhibition of NFκB signaling prevents induction of SOD2 expression and enhances tumor cell killing by 
[Pemetrexed and Sorafenib]; [Pemetrexed + Sorafenib] causes a prolonged activation of ATM which promotes tumor 
cell killing. A. Animals carrying 4T1 tumors, five days after injection, were subjected to drug treatment for 5 days as per Figure 1D. After 
seven days, animals were sacrificed and blood and tumor obtained. Clarified plasma and tumor cell lysates were then subjected to multiplex 
assays as described in the Methods to detect the plasma levels of the indicated cytokines and phosphorylation status of signal transduction 
proteins using a Bio-Rad MAGPIX multiplex instrument (total 8 animals per condition, +/- SEM). # p < 0.05 less than vehicle control 
value; ¶ p < 0.05 greater than vehicle control. B. BT474 and SUM149 cells were treated with vehicle control, [pemetrexed (0.5 µM) and 
sorafenib (2 µM)], lapatinib (1 µM), or the drugs in combination as indicated. Six h after drug treatment cells were fixed and permeabilized 
in situ and immuno-fluorescence was performed to determine the expression and the phosphorylation of the indicated proteins. C. Lower 
graph: BT474 mammary carcinoma cells were transfected with a scrambled siRNA (siSCR) or to knock down the expression of ATM. 
Twenty four h after transfection cells were treated with vehicle control or with pemetrexed (0.5 µM) and/or sorafenib (2 µM), as indicated. 
Twenty four h after treatment cells were isolated and viability determined by trypan blue inclusion (n = 3 +/- SEM). super-repressor protein 
IκB S32A S36A. Twenty four h after transfection cells were treated with vehicle control or [pemetrexed (0.5 µM) and sorafenib (2 µM)], as 
indicated. Twelve h after drug treatment cells were treated with live / dead reagent and cells examined using a Hermes WiScan microscope 
where red/yellow cells = dead; green cells = alive (+/- SEM) * p < 0.05 greater than corresponding value in CMV transfected cells.
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caused increased phosphorylation of ATM and γH2AX, 
effects that were not modulated by lapatinib (Figure 
4B). As DNA damage was occurring but was not being 
increased by lapatinib, we determined whether DNA repair 
genes whose activity can be stimulated by NFκB were 
being modulated. Treatment of cells with [pemetrexed + 
sorafenib] increased the expression of the NFκB target 
gene XRCC1, which was prevented by co-incubation 
with lapatinib. Knock down of ATM expression prevented 
the toxic interaction between sorafenib and pemetrexed 
(Figure 4C). Of note, the drug combination of [pemetrexed 
+ sorafenib] activated the AMP-dependent kinase (AMPK, 
T172 phosphorylation) earlier at 6h and 12h than the 
responses observed for single drug exposure to either 
Figure 5: [Pemetrexed + Sorafenib] killing and its enhancement by ERBB1/2 inhibition relies on elevated endoplasmic 
reticulum stress and AMPK signaling. A. Upper: SUM149 cells were transfected with a plasmid to express LC3-GFP in parallel with 
either an empty vector plasmid (CMV) or a plasmid to express dominant negative eIF2α S51A. Twenty four h after transfection cells were 
treated with vehicle control or with pemetrexed (0.5 µM) and / or sorafenib (2 µM) for 6h. Cells were imaged (10X) under fluorescent light 
(FITC channel) and afterwards under visible light. Lower left: SUM149 cells were transfected with either an empty vector plasmid (CMV) 
or a plasmid to express dominant negative eIF2α S51A or a plasmid to express GRP78 / BiP / HSPA5. Lower right: SUM149 cells were 
transfected with either a control scrambled siRNA (siSCR) or siRNA molecules to knock down the expression of Beclin1 or ATG5. Twenty 
four h after transfection cells were treated with vehicle control or with pemetrexed (0.5 µM) and sorafenib (2 µM) for 24h. Floating cells 
were re-attached to the plate by centrifugation and cell viability determined using a live / dead assay where viable cells stain green, and 
non-viable cells stain yellow and red (n = 3, +/- SEM). The effects of eIF2α S51A, GRP78, siBeclin1 and siATG5 on reducing cell killing 
were significant (p < 0.05). B. BT474 cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], Lapatinib (1 
µM), Afatinib (0.5 µM), Neratinib (0.5 µM) or the drugs in combination as indicated. Cells were fixed and permeabilized in situ 1-6h after 
drug treatment as indicated. Immuno-fluorescence was performed to determine the expression of GRP78 and the S51 phosphorylation of 
eIF2α. C. BT474 cells were transfected with a scrambled siRNA or with siRNA molecules to knock down the expression of PERK, GCN2, 
PKR or HRI. Twenty four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], afatinib 
(0.5 µM), Neratinib (0.5 µM) or the drugs in combination as indicated. Six h after drug treatment cells were fixed and permeabilized in situ 
and immuno-fluorescence was performed to determine the S51 phosphorylation of eIF2α. D. Control immuno-fluorescence / in-situ western 
assays to show the expression levels of proteins after siRNA knock down.
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sorafenib or pemetrexed (data not shown). These findings 
suggest it is the persistence of unrepaired DNA damage, 
rather than increased DNA damage, that may be a portion 
of the mechanism by which ERBB1/2/4 inhibitors enhance 
[pemetrexed + sorafenib] lethality. Finally, we expressed 
the super-repressor protein IκB S32A S36A to block NFκB 
signaling. Expression of IκB S32A S36A significantly 
enhanced [pemetrexed + sorafenib] lethality (Figure 4D). 
Our prior studies demonstrated that endoplasmic 
reticulum stress signaling and a toxic form of 
autophagosome formation and autophagy flux with release 
of lysosomal proteases was a key mechanism by which 
[pemetrexed + sorafenib] killed tumor cells [6]. Treatment 
of cells with [pemetrexed + sorafenib] increased numbers 
of intense punctate LC3-GFP staining autophagosomes 
in cells in an eIF2α -dependent mechanism (Figure 5A, 
Figure 6: [Pemetrexed + Sorafenib] treatment regulates the expression of multiple chaperone proteins and plasma 
membrane drug efflux pumps. A. SUM149 cells were treated with vehicle control or [pemetrexed (0.5 µM) and sorafenib (2 µM)] 
for 6h. Six h after drug treatment cells were fixed and permeabilized in situ and immuno-fluorescence was performed to determine the 
expression of chaperone proteins and drug efflux pumps. B. A GST-HSP90 NH2-terminal fragment containing the ATP binding domain 
of the chaperone was synthesized in E. coli and purified from other bacterial proteins using glutathione sepharose. The GST-HSP90 NH2-
terminal fragment protein was not eluted off the sepharose beads. Equal portions of beads were immediately aliquoted into individual wells 
in a 96 well plate. Beads were resuspended in kinase reaction buffer containing vehicle control; sorafenib tosylate; regorafenib; (30 nM; 
100 nM; 300 nM; 1 µM) in triplicate, and incubated for 30 min at 37 oC. The reaction was started by addition of ATP-lite substrate. The 
plate was removed from the incubator and placed into a Vector 3 plate reader to determine the luminescence of the reactions under each 
treatment condition (n = 3 (x 3) +/- SEM). C. and D. GBM12 cells were transfected with a plasmid to express HSP70-GFP or to express 
FLAG-tagged HSP90. Twenty four h after transfection cells were treated with vehicle control or sildenafil (2 µM) for 1h. Chaperone 
proteins were immuno-precipitated using their tags in the presence of phosphatase inhibitors. Equal portions of precipitate sepharose beads 
were immediately aliquoted into individual wells in a 96 well plate. Beads were resuspended in ATPase reaction buffer containing vehicle 
control; sorafenib tosylate; afatinib; (30 nM; 100 nM; 300 nM; 1 µM; 2 µM) in triplicate, and incubated for 30 min at 37 oC. The reaction 
was started by addition of ATP-lite substrate. The plate was removed from the incubator and placed into a Vector 3 plate reader to determine 
the luminescence of the reactions under each treatment condition (n = 3 (x 3) +/- SEM).
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upper). Expression of dominant negative eIF2α S51A, 
over-expression of GRP78 or knock down of Beclin1 
or ATG5 protected cells from [pemetrexed + sorafenib] 
lethality (Figure 5A, lower). Treatment of BT474 cells 
with [pemetrexed + sorafenib] reduced expression of 
the endoplasmic reticulum chaperone GRP78 (Figure 
5B, upper). Notably the combination of [pemetrexed 
+ sorafenib] with an ERBB1/2/4 inhibitor more rapidly 
promoted the reduction in GRP78 expression compared 
to the individual drugs. The reductions in GRP78 
expression correlated with increased phosphorylation of 
the endoplasmic reticulum stress mediator eIF2α (Figure 
Figure 7: [Pemetrexed + sorafenib] lethality is reduced by over-expression of GRP78, HSP70 and HSP90. A. GBM12 
cells were transfected with empty vector control (CMV) or with plasmids to express HSP27, GRP78, HSP70 or HSP90, alone or in 
combination as indicated. Twenty four h after transfection cells were treated with vehicle control or with [pemetrexed (1.0 µM) + sorafenib 
(2.0 µM)] for 24h. Cell viability determined using a live / dead assay where viable cells stain green, and non-viable cells stain yellow and 
red (n = 3, +/- SEM) * p < 0.05 less than corresponding CMV value; **p < 0.05 less than value obtained in single transfection to express 
HSP70. B. GBM12 cells were transfected with empty vector control (CMV) or with plasmids to express HSP27, GRP78, HSP70 or HSP90, 
alone or in combination as indicated. Twenty four h after transfection cells were treated with vehicle control or with [pemetrexed (1.0 µM) 
+ sorafenib (2.0 µM)] for 6h. Six h after drug treatment cells were fixed and permeabilized in situ and immuno-fluorescence was performed 
to determine the expression of the proteins c-FLIP-s, MCL-1 or thioredoxin (TRX). C. Left panels: GBM12 cells were treated for 2h with 
[pemetrexed (1.0 µM) and sorafenib (2.0 µM)] after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-
fluorescence was performed to detect the expression levels of CDC37 and the phosphorylation of CDC37 S13 at 10X magnification. Right 
panels: GBM12 cells were treated with vehicle, [pemetrexed (1.0 µM) + sorafenib (2.0 µM)] for 6h after which cells were fixed in place 
and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the co-localization of CDC37 and HSP90 at 
60X magnification. D. Left: BT474 and SUM149 cells were treated for 2h with vehicle or with [pemetrexed (0.5 µM) and sorafenib (2 
µM)]. Two h after drug treatment cells were fixed and permeabilized in situ and immuno-fluorescence was performed to determine the 
expression of the HSPH1 / p105 chaperone protein and c-MYC protein at 10X magnification, and the co-localization of p105 and c-MYC at 
60X magnification. Right: BT474 and SUM149 cells were treated for 6h with vehicle control or with [pemetrexed (0.5 µM) and sorafenib 
(2 µM)]. Six h after drug treatment cells were lysed and either p105 or c-MYC immuno-precipitated. Immuno-precipitates of p105 were 
subjected to SDS PAGE and immuno-blotting performed to determine the expression / association of c-MYC. Immuno-precipitates of 
c-MYC were subjected to SDS PAGE and immuno-blotting performed to determine the expression / association of p105.
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5B, lower). Multiple kinases phosphorylate eIF2α, and 
we discovered that knock down of PKR-like endoplasmic 
reticulum kinase (PERK) most effectively suppressed 
the phosphorylation of eIF2α caused by [pemetrexed 
+ sorafenib] and by the combination of an ERBB1/2/4 
inhibitor with [pemetrexed + sorafenib] (Figure 5C). See 
also Figure 5D for control images of protein expression 
and molecular knock down effects. 
In multiple studies over the past decade we have 
shown that sorafenib can increase endoplasmic reticulum 
stress signaling in part by reducing the expression of 
chaperone proteins as well as expression of drug efflux 
pumps [17, 18, 21-24]. Treatment of breast cancer cells 
with [pemetrexed + sorafenib] reduced the immuno-
fluorescence detection of the chaperone proteins HSP90, 
GRP78, HSP70, HSP60, HSP40, HSP27, HSP10 as well 
as the multi-drug efflux pumps ABCB1 and ABCG2 
(Figure 6A). Sorafenib, but not regorafenib or afatinib, 
inhibited the ATPase activities of bacterial synthesized 
HSP90 and eukaryotic cell synthesized HSP90 and 
Figure 8: Killing by [pemetrexed + sorafenib + afatinib] requires ER stress signaling as well as inactivation of AKT 
and PERK dephosphorylation. A. BT474 and SUM149 cells were transfected with a scrambled siRNA or with an siRNA molecule 
to knock down the expression of PERK. Twenty four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) 
and sorafenib (2 µM)], Afatinib (0.5 µM), Neratinib (0.5 µM) or the drugs in combination as indicated. Twelve h after treatment cells 
were treated with live / dead reagent and cells examined using a Hermes WiScan microscope where red/yellow cells = dead; green cells = 
alive. B. BT474 and SUM149 cells were transfected with an empty vector plasmid (CMV) or with a plasmid to express GRP78. Twenty 
four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], Afatinib (0.5 µM), Neratinib 
(0.5 µM) or the drugs in combination as indicated. Twelve h after treatment cells were treated with live / dead reagent and cells examined 
using a Hermes WiScan microscope where red/yellow cells = dead; green cells = alive. C. SUM149 cells were treated for 6h with vehicle 
control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], Afatinib (0.5 µM) or the drugs in combination as indicated. Cells were fixed and 
permeabilized in situ and immuno-fluorescence was performed to determine the total phosphorylation level at 10X magnification of PERK 
T981; PERK T799; and AKT T308. D. SUM149 cells were transfected with a scrambled siRNA or with siRNA molecules to knock down 
the expression of AMPKα1/α2, PERK, ATF4 or CHOP. Twenty four h after transfection cells were treated with vehicle control, [pemetrexed 
(0.5 µM) and sorafenib (2 µM)], Afatinib (0.5 µM) or the drugs in combination as indicated. Twelve h after treatment cells were treated with 
live / dead reagent and cells examined using a Hermes WiScan microscope where red/yellow cells = dead; green cells = alive (+/- SEM) 
* p < 0.05 less than siSCR control value. 
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eukaryotic cell synthesized HSP70 (Figures 6B-6D). 
Treatment of cells for 60 min with the phosphodiesterase 
5 inhibitor sildenafil (Viagra) enhanced the ability of 
sorafenib to inhibit chaperone ATPase activities in vitro; 
the chaperones having been isolated from eukaryotic cells 
by immuno-precipitation.
Over-expression of GRP78, HSP70 or HSP90 
significantly reduced the lethality of [pemetrexed + 
sorafenib] (Figure 7A). Although over-expression of 
HSP27 did not protect cells from [pemetrexed + sorafenib] 
expression of HSP27 in the presence of HSP70, HSP27 did 
enhance the cyto-protective effect of HSP70. Downstream 
Figure 9: Knock down of [BAX + BAK], [NOXA + PUMA], AIF or over-expression of BCL-XL protects tumor cells 
from [pemetrexed + sorafenib + afatinib] toxicity. A. SUM149 cells were transfected with a scrambled siRNA molecule or with 
the siRNA molecules shown in the Figure. Twenty four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) 
and sorafenib (2 µM) and afatinib (0.5 µM) in combination as indicated. Twelve h after treatment cells were treated with live / dead reagent 
and cells examined using a Hermes WiScan microscope where red/yellow cells = dead; green cells = alive (+/- SEM). * p < 0.05 less than 
siSCR value. B. SUM149 cells were transfected with an empty vector plasmid or with the protein expression plasmids shown in the Figure. 
Twenty four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM) and afatinib (0.5 µM) 
in combination as indicated. Twelve h after treatment cells were treated with live / dead reagent and cells examined using a Hermes WiScan 
microscope where red/yellow cells = dead; green cells = alive. alive (+/- SEM). * p < 0.05 less than siSCR value. C. and D. SUM149 cells 
were transfected with a scrambled siRNA molecule or with the siRNA molecules shown in the Figure to knock down Beclin1 or BID. 
Twenty four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM) and afatinib (0.5 µM) 
in combination as indicated. Cells were isolated and broken down using a CHAPS based lysis buffer with vigorous trituation, followed by 
lysate clarification via centrifugation (5 min x 14,000 g) Equal protein mass portions of lysates were immuno-precipitated using antibodies 
that recognize epitopes in BAX and in BAK only open to detection when these toxic BH3 domain proteins are active. Immuno-precipitates 
of active BAX and of active BAK are run on SDS PAGE (14%) and electrophoresed proteins transferred to 0.22 µm thick nitro-cellulose 
membranes for immuno-blotting against the total expression of BAX and of BAK under each condition. In parallel, a small portion of cell 
lysate is run alongside the immuno-precipitate as a control for total BAX/BAK expression. E. SUM149 cells were transfected with the 
indicated siRNA molecules and 24h after transfection the expression of the indicated proteins was determined by immuno-fluorescence. 
SUM149 cells were transfected with plasmids to make the indicated proteins 24h after transfection the expression of the indicated proteins 
was determined by immuno-fluorescence.
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of the chaperones, over-expression of [HSP27 + GRP78]; 
[HSP27 + HSP70]; and [HSP70 + HSP90] enhanced 
the basal expression of thioredoxin (TRX), MCL-1 and 
c-FLIP-s, and diminished the ability of [pemetrexed + 
sorafenib] to reduce their protein expression (Figure 
7B). HSP90 function is controlled in part by its essential 
co-chaperone CDC37. CDC37, when phosphorylated 
on Serine 13 by casein kinase 2, facilitates HSP90 
chaperoning of cyclin dependent kinases, IκB kinases and 
eIF2α kinases. Serine 13 phosphorylation is thought to 
stabilize CDC37 into a more compact conformation with 
enhanced secondary structure. A 2h exposure of cells to 
[pemetrexed + sorafenib] reduced the phosphorylation of 
CDC37 Serine 13 without any apparent change in the total 
expression of CDC37 itself at that 2h time point (Figure 
7C, left panels). In co-localization studies (i.e. red + green 
= yellow), we noted that at the 6h incubation time point 
[pemetrexed + sorafenib] treatment had reduced the total 
expression of both HSP90 and of CDC37 themselves and 
decreased the amount of CDC37-HSP90 co-localization 
(i.e. reduced yellow staining; increased red-orange 
staining) (Figure 7C, right panels). The oncogenic 
transcription factor c-MYC is known to be chaperoned in 
part by the chaperones HSPH1/p105, HSP60 and HSP27. 
In agreement with the drug combination causing chaperone 
dysfunction, treatment of tumor cells with [pemetrexed + 
sorafenib] reduced c-MYC - p105 co-localization in the 
nucleus without apparently altering the total amount of 
nuclear localized c-MYC protein (Figure 7D). We also 
observed increased numbers of vesicles in the cytosol of 
[pemetrexed + sorafenib] treated cells that contained high 
levels of HSPH1/p105 but very low levels of c-MYC. In 
agreement with the apparent reduced association in the 
nucleus between c-MYC and HSPH1/p105, the amount 
of HSPH1/p105 co-immuno-precipitating with c-MYC 
and the amount of c-MYC co-immuno-precipitating with 
HSPH1/p105 were both reduced by ~50% following 
[pemetrexed + sorafenib] exposure (Figure 7D, blots to 
the right). Thus [pemetrexed + sorafenib] treatment by 
inhibiting the function of HSPH1/p105, also reduces 
c-MYC function.
We then explored the roles of GRP78 and 
endoplasmic reticulum signaling in drug combination 
lethality. Molecular knock down of PERK expression 
protected tumor cells from ERBB1/2 inhibitor + 
[pemetrexed + sorafenib] lethality (Figure 8A). Over-
expression of the PERK inhibitory chaperone GRP78 
suppressed drug-induced eIF2α phosphorylation and 
blocked tumor cell killing by the drug combinations 
(Figure 8B, data not shown). The data in Figure 8A 
correlated with the drug combination reducing AKT 
T308 phosphorylation and reducing the phosphorylation 
of PERK at T799, a site of AKT-induced inhibitory 
phosphorylation on PERK, and increasing PERK 
T981 phosphorylation, a site of stimulatory auto-
phosphorylation, which collectively will cause a hyper-
activation of PERK (Figure 8C). Knock down of 
PERK, ATF4 or CHOP expression, both upstream and 
downstream effectors of eIF2α, also reduced tumor cell 
death (Figure 8D). Knock down of the AMP dependent 
protein kinase alpha subunit suppressed drug combination 
lethality in agreement with prior data showing pemetrexed 
stimulates ZMP production [1, 2]. 
Combined knock down of BAX+BAK or 
NOXA+PUMA or of AIF alone, or over-expression of 
BCL-XL partially protected cells from [pemetrexed + 
sorafenib + afatinib] -induced killing (Figures 9A and 9B). 
Knock down of CD95 or over-expression of c-FLIP-s did 
not reduce drug-induced cell killing which is in general 
congruence with our prior findings that CD95 null 
HuH7 hepatoma cells were effectively killed by the drug 
combination [6]. AIF appeared to play a greater role in 
mediating death signals down-stream of mitochondria than 
did caspase 9. Also notable was that BID activation down-
stream of autolysosomes appeared to be playing a greater 
role in cell killing than caspase 8 signaling, suggesting 
cathepsin and calpain proteases rather than caspase 8 
were causing BID cleavage. Knock-down of Beclin1 or 
of BID suppressed the [pemetrexed + sorafenib] -induced 
activations of BAX and of BAK (Figure 9C). However, 
knock down of BID did not block BAX activation caused 
by [pemetrexed + sorafenib + afatinib], despite knock 
down of Beclin1 still reducing BAX activation (Figure 
9D). These findings argue that [pemetrexed + sorafenib] 
and [pemetrexed + sorafenib + afatinib] -induced 
stimulation of autophagosome / autolysosome formation 
plays a central role, upstream of mitochondria and toxic 
BH3 domain proteins, by which these drug combinations 
drive forwards tumor cell killing. Confirmatory knock 
down assessments for the proteins are presented in Figure 
9E.
As the drug combinations were increasing vesicle / 
autophagosome levels that were an essential component 
in tumor cell killing, we next investigated the upstream 
signaling pathways that regulate autophagy. Treatment 
of cells with [pemetrexed + sorafenib] or [pemetrexed 
+ sorafenib + afatinib] reduced mTOR S2448 
phosphorylation and decreased phosphorylation of ULK-
1 S757, which is the site in ULK-1 phosphorylated by 
mTOR to keep the ULK-1 kinase inactive (Figure 10A). 
The drug combination treatments with pemetrexed also 
increased ULK-1 S317 phosphorylation, which is one 
known site of AMP-dependent protein kinase (AMPK) 
phosphorylation, and is a site whose phosphorylation acts 
to that stimulate ULK-1 activity. The observed changes 
in both ULK-1 phosphorylation sites correlated with 
increased ATG13 S318 phosphorylation (Figure 10A). At 
60X magnification co-localization of LC3 (ATG8) and 
phospho-S318 ATG13 was observed after [pemetrexed + 
sorafenib] or [pemetrexed + sorafenib + afatinib] treatment 
(Figure 10B). Treatment of cells with [pemetrexed + 
sorafenib] or [pemetrexed + sorafenib + afatinib] increased 
Oncotarget23620www.impactjournals.com/oncotarget
total Beclin1 and ATG5 expression in an eIF2α -dependent 
manner (Figure 10C). Knock down of Beclin1 or ATG5 
or eIF2α reduced the lethality of [pemetrexed + sorafenib 
+ afatinib] (Figure 10D). Thus the drug combinations: 
[pemetrexed + sorafenib] +/- ERBB1/2/4 inhibitor 
facilitate a toxic form of autophagy both by increasing 
autophagy regulatory Beclin1 / ATG5 protein expression 
through endoplasmic reticulum stress signaling and by 
also reducing GRP78 and HSP27 chaperone functions 
thereby differentially altering protein phosphorylation of 
mTOR / ULK-1 / ATG13 collectively, to facilitate toxic 
autophagosome / autolysosome formation. 
The phosphorylation of proteins is not only 
dependent upon the actions of protein kinases, but also 
on those of protein phosphatases [26, 27]. It has been 
shown that the catalytic subunit of serine / threonine 
protein phosphatase 1, PP1c, localizes to autophagosomes 
through its targeting subunit ATG16L1 [28-30]. Six h 
after treatment of vector control transfected SUM149 
cells with [pemetrexed + sorafenib], PP1c and phospho-
ATG13 co-localized, as judged by the increase in the 
yellow fluorescent signal (Figure 11). The co-localization 
Figure 10: Pemetrexed + Sorafenib + Afatinib promote autophagy through ER stress -induced expression of Beclin1 
and LC3, and by mTOR inactivation and AMPK activation leading to ATG13 phosphorylation. A. BT474 cells were 
treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], afatinib (0.5 µM), or the drugs in combination as indicated. 
Six h after drug treatment cells were fixed and permeabilized in situ and immuno-fluorescence was performed to determine the levels of: 
P-mTOR S2448; P-ULK-1 S757; P-ULK-1 S317; P-ATG13 S318. B. BT474 cells were treated with vehicle control or with [pemetrexed 
(0.5 µM) + sorafenib (2 µM) + afatinib (0.5 µM)] in combination as indicated. Six h after drug treatment cells were fixed and permeabilized 
in situ and immuno-fluorescence was performed at 60X magnification to determine the co-localization of phosphorylated ATG13 (red 
fluorescent stain) and LC3 (green fluorescent stain). C. BT474 cells were transfected with a scrambled siRNA or an siRNA to knock 
down expression of eIF2α. Twenty four h after transfection cells were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib 
(2 µM)], afatinib (0.5 µM), or the drugs in combination as indicated. Six h after drug treatment cells were fixed and permeabilized in situ 
and immuno-fluorescence was performed to determine the levels of: Beclin1 and ATG5. D. BT474 cells were transfected with a scrambled 
siRNA or with siRNA molecules to knock down expression of Beclin1, ATG5 or eIF2α. Twenty four h after transfection cells were treated 
with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], afatinib (0.5 µM), or the drugs in combination as indicated. Cell viability 
was determined 12h after drug exposure (+/- SEM) * p < 0.05 less than corresponding value in siSCR treated.
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of PP1c with phospho-ATG13 declined in vector control 
transfected cells treated with [pemetrexed + sorafenib 
+ afatinib]. Over-expression of [GRP78 + HSP27] 
increased the basal levels of PP1c expression and 
maintained the co-localization of PP1c with phospho-
ATG13 under all treatment conditions. Thus the GRP78 
and HSP27 chaperones, by increasing and maintaining 
PP1c association with ATG13, prevent drug-stimulated 
autophagic flux towards tumor cell death. 
Phosphorylation of ATG16L1 at S139 by casein 
kinase 2 has been postulated as one mechanism by 
which PP1c dissociates from the autophagosome, 
enhancing ATG13 S318 phosphorylation and as a result 
autophagosome formation [28]. A threonine 300 to alanine 
300 variation in ATG16L1, which has a ~50% penetrance 
in European populations but is much less frequently 
found in African-American populations (~5%), has been 
implicated in the development of Crohn’s Disease and 
an inability of bacteria to be phagocytosed by cells and 
then disposed of by digestion in autophagic vesicles 
[31, 32]. In cell viability assays, treatment of wild type 
HCT116 cells that are homozygous for ATG16L1 T300 
T300 with [pemetrexed + sorafenib] resulted in high 
levels of tumor cell killing as we have generally observed 
in many tumor cell types (Figure 12A). In isogenic 
ATG16L1 -/- null cells, that are autophagy incompetent, 
the lethality of [pemetrexed + sorafenib] was, as expected, 
significantly reduced. In isogenic HCT116 cells that have 
been genetically modified to homozygously express the 
ATG16L1 variant A300; [pemetrexed + sorafenib] killed 
these HCT116 A300 cell variants with the levels of cell 
killing being significantly lower than observed in HCT116 
T300 T300 cells, with values intermediate between those 
found in ATG16L1 T300 T300 cells and in the -/- null cells 
(p < 0.05).
Based on these findings, we determined in the 
isogenic HCT116 cells the basal and drug-induced changes 
in the phosphorylation of ATG13 S318; ULK1 S757; 
and mTOR S2448. The basal phosphorylation of ATG13 
S318 was low in wild type HCT116 cells that express 
ATG16L1 T300 T300 (Figure 12B). This correlated 
with high basal phosphorylation of mTOR S2448 and 
of ULK1 S757. In ATG16L1 null -/- cells, the basal 
phosphorylation of mTOR and ULK1 was reduced, and 
the basal phosphorylation of ATG13 S318 increased. In 
ATG16L1 A300 A300 cells, the basal phosphorylation of 
mTOR and ULK1 was very low and the phosphorylation 
of ATG13 high. Treatment of HCT116L1 T300 T300 cells 
with [pemetrexed + sorafenib] or [pemetrexed + sorafenib 
+ afatinib] reduced ULK1 S757 phosphorylation and 
mTOR S2448 phosphorylation and increased ATG13 
S318 phosphorylation. In contrast, treatment of HCT116 
Figure 11: GRP78 and HSP27 regulate the co-localization of PP1c and ATG13. SUM149 cells were transfected with an empty 
vector plasmid (CMV) or plasmids to express GRP78 and HSP27. Twenty four h after transfection cells were treated for 3h with vehicle 
control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], afatinib (0.5 µM), or the drugs in combination as indicated. After 3h cells were fixed 
and permeabilized in situ and immuno-fluorescence was performed to determine the co-localization at 60X magnification of P-ATG13 S318 
(red) and PP1c (green). 
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ATG16L1 A300 A300 cells with [pemetrexed + sorafenib] 
or [pemetrexed + sorafenib + afatinib] only modestly 
reduced mTOR and ULK1 phosphorylation and had no 
apparent effect on ATG13 S318 phosphorylation.
One hypothetical way to explain more completely 
these protein phosphorylation findings would be 
if the localization of PP1c, via ATG16L1, with the 
autophagosome, changed during drug exposure, as we 
very likely were observing in the SUM149 breast cancer 
cells. Under basal conditions in both ATG16L1 T300 T300 
and ATG16L1 A300 A300 cells, we discovered that PP1c 
co-localized with phospho-ATG13 S318, with an apparent 
greater level of PP1c-ATG13 co-localization in T300 T300 
cells compared to the A300 A300 cells as judged by the co-
localization signal being a reddish orange-yellow (Figures 
S1-S3). Upon exposure of ATG16L1 T300 T300 cells to 
[pemetrexed + sorafenib] the co-localization of PP1c with 
ATG13 S318 was reduced as judged by the co-localization 
signal becoming a reddish orange-yellow similar to that 
observed in vehicle control A300 A300 cells. Exposure 
of ATG16L1 T300 T300 cells to [pemetrexed + sorafenib 
+ afatinib] abolished the co-localization of PP1c with 
ATG13 S318, whereas in ATG16L1 A300 A300 cells 
PP1c still co-localized with ATG13 S318 albeit at a 
reduced level. Collectively, these data would suggest that 
the phosphorylation of ATG16L1 Threonine 300 plays a 
very important role in regulating PP1c localization within 
the autophagosome complex after [pemetrexed + sorafenib 
+/- afatinib] exposure. As cells expressing ATG16L1 
T300 T300, the variant predominantly found in African-
Americans, respond more favorably to [pemetrexed + 
sorafenib +/- afatinib] than ATG16L1 A300 A300 cells, 
a phenotype more predominantly found in European-
Americans; our findings may have wider societal 
implications for the delivery of pemetrexed based or other 
autophagy utilizing cancer therapies.
We next determined whether the ERBB1/2/4 
inhibitors lapatinib and afatinib or the VEGFR2/ERBB1/4 
inhibitor vandetanib could enhance [pemetrexed + 
sorafenib] toxicity in human breast and human lung 
cancer models. Using orthotopic BT474 HER2+ human 
mammary tumors in an athymic mouse, a single 5 day 
treatment cycle with lapatinib or vandetanib (ZD6474) 
enhanced the anti-tumor effects of [pemetrexed + 
sorafenib] (Figure 13A, *p < 0.05). Using H1975 double 
mutant active ERBB1 T790M L858R expressing non-
small cell lung cancer cells growing in athymic mice, a 
single shorter 4 day treatment cycle with afatinib enhanced 
Figure 12: Genetic variants of ATG16L1 alter the lethality of [pemetrexed + sorafenib] +/- afatinib to kill colon cancer 
tumor cells. A. HCT116 clones were treated with vehicle control, [pemetrexed (0.5 µM) and sorafenib (2 µM)], afatinib (0.5 µM) or the 
drugs in combination as indicated. Twelve h after treatment cells were treated with live / dead reagent and cells examined using a Hermes 
WiScan microscope where red/yellow cells = dead; green cells = alive. B. HCT116 clones were treated with vehicle control, [pemetrexed 
(0.5 µM) and sorafenib (2 µM)], afatinib (0.5 µM) or the drugs in combination as indicated. Twelve h after treatment cells were fixed and 
permeabilized in situ and immuno-fluorescence was performed to determine the total phosphorylation levels at 10X magnification of ATG 
S318; ULK1 S757; mTOR S2448.
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the anti-tumor effects of [pemetrexed + sorafenib] (Figure 
13B, *p < 0.05). Cell killing was specific to tumor cells, 
and treatment of animals with [pemetrexed + sorafenib + 
lapatinib] for 5 days did not alter animal body mass or 
cause normal tissue damage as judged by H&E staining 
(Figure 13C, data not shown). In the phase I trial, daily 
treatment of sorafenib with Q 2 week pemetrexed resulted 
in cumulative toxicities in some patients who remained 
on the trial for > 6 months, and the RP2D and schedule 
for the phase II trial is for pemetrexed Q 2 weeks with 
sorafenib dosing on days 1-5. Should our proposed three-
drug studies eventually move to the clinic it is probable 
that the dosing of patients with pemetrexed, sorafenib 
and afatinib, all of which can cause GI dysfunction and 
reduce blood cell production as well as skin and mouth 
lesions (afatinib, sorafenib), will again need to be carefully 
planned so as not to elicit dose-limiting-toxicities within 
the first cohort / dosing level. Furthermore, because of 
these issues, and considering the liver metabolism and 
excretion of the drugs, it is possible that the PK / PD of 
each agent will be modified by the inclusion of each of the 
other agents; as we have observed alterations in ABCB1 
and ABCG2 expression, altered drug accumulation in 
normal tissues may also become an issue in the design of 
any new phase I trial.
As reported at the 2015 ASCO meeting, treatment 
of recurrent solid tumor patients with [pemetrexed + 
sorafenib] resulted in ~60% of all patients experiencing 
some degree of tumor growth delay (SD, PR, CR), with 
multiple partial responses and one complete response 
Figure 13: [Pemetrexed + Sorafenib] treatment extends animal survival and is enhanced by inhibition of ERBB1/2 
signaling. A. BT474 cells (1 x 107) were infused into the 4th mammary fat pad of athymic mice and permitted to establish for 7 days. 
Animals were treated for 5 days with vehicle diluent (cremophore); sorafenib, pemetrexed, lapatinib or ZD6474 (vandetanib), or in the 
indicated combinations by oral gavage for 5 days. (n = 8-10 per group +/- SEM) * p < 0.05 lower tumor volume than pemetrexed + 
sorafenib treatment alone. B. H1975 cells (1 x 107) were infused into rear flank of athymic mice and permitted to establish for 7 days. 
Animals were treated for 5 days with vehicle diluent (cremophore); sorafenib, pemetrexed, afatinib, or in the indicated combinations in 
the Methods by oral gavage for 5 days. (n = 10 per group +/- SEM) * p < 0.05 lower tumor volume than pemetrexed + sorafenib treatment 
alone. C. Animals from panel A, at the time of sacrifice 19 days after cessation of drug treatment, were dissected and their “normal” tissues 
obtained. Tissues were fixed, sectioned and H&E stained.
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(NCT01450384) [20]. In our phase I trial we found that 
even within a large tumor that profoundly responded to 
treatment, individual portions of the tumor displayed 
various forms of response against the [pemetrexed + 
sorafenib] drug combination (Figures 14A-14C). The 
patient in Figure 14 was treated at the lowest dose level 
of 500 mg/m2 pemetrexed and 200 mg BID sorafenib. 
The patient in Panel A is a pre-treatment image of a triple 
negative mammary carcinoma that had previously received 
10 prior therapeutic interventions; the image in Panel B is 
after 4 months of [pemetrexed + sorafenib] therapy; that 
in Panel C is after 5 months of [pemetrexed + sorafenib] 
therapy when the patient had to leave the trial due to 
tumor progression. The tumor labeled with the blue arrow 
completely resolved after treatment whereas the portion of 
the tumor labeled with the green arrow displayed a cyto-
static effect. The tumor material labeled with the red arrow 
initially strongly responded to the drug combination, but 
note that portions of the tumor then displayed re-growth 
after 5 months. From this data we conclude that any anti-
cancer drug combination, even one as multi-mechanistic 
and as potent as [pemetrexed + sorafenib], which is 
designed to only kill a highly specific subset of tumor cells 
i.e. the idealized “personalized medicine approach” that 
is being touted by the medical community to the public 
at large, will be unlikely to provide any true long-term 
/ curative benefit to the majority of patients who carry 
multiple clonal variants of the same tumor at the same 
time.
As part of NCT01450384, sections of pre-therapy 
archived tumor blocks from patients were subjected 
to immuno-histochemistry by a certified pathologist 
to determine the basal expression levels of the tumor 
suppressor PTEN. Differences were seen in the expression 
levels of PTEN between patients, with some tumors 
exhibiting very high levels; some low levels; and some 
tumors that were PTEN null (Figure 14D). There are a very 
large number of studies over the last 25 years which that 
state loss of PTEN results in resistance to many diverse 
forms of chemotherapy and radiotherapy; the clinical 
Figure 14: Individual clonal re-growth of mammary carcinoma in a patient treated with [pemetrexed + sorafenib]. A.-
C. This triple negative mammary carcinoma patient had received 10 prior therapies before recruitment onto the phase I trial NCT01450384, 
and was the second patient on the trial at the lowest dose level (200 mg BID sorafenib; 500 mg / m2 pemetrexed). Data in Panel A shows 
the extent of the cutaneous tumor prior to therapy. Data in Panel B shows the response of the tumor four months after the start of therapy. 
Data in Panel C shows the response of the tumor after 5 months, and with the start of some clonal tumor re-growth. The colored arrows, 
indicate tumors that responded with either a CR (blue), stable disease (green), or a PR followed by disease progression (red). D. Pre-
treatment paraffin embedded tumor material from each patient was sectioned, de-paraffinized and subjected to antigen retrieval. All slides 
had previously been immuno-stained using DAB conversion to detect PTEN protein expression levels [20]. Visible light images of DAB 
staining for PTEN is presented.
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observation that a reduction or loss of PTEN expression 
significantly correlates with enhanced therapeutic effects 
of any drug combination has not been reported. The 
ordinal regression statistical results from the trial indicate 
a significant association between no or low expression 
levels of PTEN and patient response (p = 0.013) [20]. 
As part of the studies in Figure 13B, we also 
generated by in vivo high dose afatinib (50 mg/kg BID) 
for 4 days treatment afatinib resistant H1975 cells (5 
tumors / clones of control; 5 tumors / clones of afatinib 
resistant) [34, 35]. Afatinib caused H1975 flank tumors 
to completely disappear for approximately one week 
and then the tumors slowly began to re-grow. We then 
performed multiplex assays on portions of tumor tissue 
from tumors in Figure 13B as well as the afatinib resistant 
tumors taken at the time of mouse sacrifice due to tumor 
volume after ~30 days. Afatinib resistant H1975 tumors 
contained higher expression levels of the human cytokines 
CXCL-1, IL-6 and IL-8 and expressed higher basal levels 
of the IL-8 receptor (Figure S4A). Knock down of the IL-8 
receptor enhanced [pemetrexed + sorafenib] lethality in 
afatinib resistant H1975 cells. Afatinib resistant H1975 
tumors contained higher levels signaling within their PI3K 
and NFκB pathways compared to control tumors (Figures 
S4A-S4D). Based on the multiplex data showing increased 
PI3K pathway activity in afatinib resistant H1975 clones 
and in [pemetrexed + sorafenib + afatinib] resistant clones 
we next determined whether inhibition of PI3K signaling 
enhanced [pemetrexed + sorafenib] lethality and whether 
any changes in PTEN expression and its Serine 380 
regulatory phosphorylation could be found in our in vivo 
generated afatinib resistant H1975 clones. Inhibition of 
PI3K signaling using the phase III PI3Kα/β/γ/δ inhibitor 
drug copanlisib enhanced [pemetrexed + sorafenib] 
toxicity in afatinib-resistant H1975 clones to a greater 
extent than it did in control H1975 clones (Figure S4E, 
p < 0.05).
Expression of PTEN was considerably reduced 
in afatinib resistant H1975 tumor clones compared 
to control clones that correlated with elevated AKT 
T308 phosphorylation (Figure S5A). Afatinib resistant 
H1975 clones also exhibited lower levels of PTEN S380 
phosphorylation compared to control clones. Based 
on image density analyses the ratio of PTEN S380 
phosphorylation to total PTEN expression was 0.31 in 
control clones which was significantly lower than the 
ratio found in afatinib resistant cells which was 0.52 (p < 
0.05). This finding shows afatinib resistant H1975 clones, 
by virtue of expressing less PTEN and having a greater 
proportion of this PTEN phosphorylated at Serine 380 and 
thus inactive, will permit more active signaling from PI3K 
through PTEN and downstream into AKT / mTOR than 
will control clones. 
Afatinib resistant clones had higher basal expression 
of Beclin1, lower expression of PP2Ac and CHOP, and 
higher basal phosphorylation of ULK-1 S317, ULK-1 
S757 and ATG13 S318, which correlated with elevated 
autophagosome levels (Figures S5B and S5C). Treatment 
of control and afatinib resistant clones with [pemetrexed 
+ sorafenib] or [pemetrexed + sorafenib + afatinib] 
reduced mTOR S2448 phosphorylation and decreased 
phosphorylation of ULK-1 S757, which is the site in 
ULK-1 phosphorylated by mTOR to keep the kinase 
inactive (Figure S5D). The observed changes in both 
ULK-1 phosphorylation sites correlated with increased 
ATG13 S318 phosphorylation (Figure S5E). Thus 
the patient tumors most responsive to [pemetrexed + 
sorafenib] expressed lower PTEN as did afatinib-resistant 
H1975 tumors; and afatinib synergized with [pemetrexed 
+ sorafenib] to kill in vitro and in vivo. Previously we 
noted that tumor cell types that displayed high levels 
of cell killing after [pemetrexed + sorafenib] exposure, 
such as MCF7F, H460 and HuH7 tended to exhibit 
significantly elevated basal levels of AKT, p70 S6K and/or 
mTOR phosphorylation [6]. Hence we also postulate the 
possibility that just as a mutated active ERBB1-addicted 
tumor cell may be attempting to evolve away from afatinib 
sensitivity by reducing its PTEN levels, it could encounter 
[pemetrexed + sorafenib] therapy which preferentially 
kills those cells expressing low PTEN. 
Finally, because of these findings we performed 
additional assays, knocking down PTEN expression 
in tumor cells and determining whether this altered 
the killing response to [pemetrexed + sorafenib] and 
[pemetrexed + sorafenib + afatinib]. Using H1975 lung 
tumor cells that express a wild type PTEN, knock down of 
PTEN expression enhanced the lethality of [pemetrexed + 
sorafenib] but not of [pemetrexed + sorafenib + afatinib] 
where killing was observed as being > 50% of the cell 
regardless of the cellular PTEN status. (Figure S6A) [40, 
44]. Expression of wild type PTEN in the PTEN null 
glioblastoma cell line GBM14 reduced the efficacy of 
[pemetrexed + sorafenib] or [pemetrexed + sorafenib + 
afatinib] but increased the killing power of afatinib as a 
single agent (Figure S6B). 
The precise reasons why paradoxically both 
inhibition of PI3K and loss of PTEN can both enhance 
[pemetrexed + sorafenib] lethality will require many 
additional studies. However, one possible explanation 
for this effect could be suggested by some additional data 
hewed from the afatinib resistant H1975 clones. In the 
afatinib resistant clones, where PTEN levels were low, 
we noted that expression of the negative transcriptional 
regulator of the PTEN gene, NEDD4, was much higher 
than in control clones, and that the expression of another 
NEDD4 target and PTEN-associated protein, PTPN13 
(FAP-1), was also low (Figure S5F) [36]. PTPN13 is a 
protein tyrosine phosphatase that is localized in the plasma 
membrane environment by its PDZ domains to PTEN, 
where PTPN13 was originally described as the tyrosine 
phosphatase that dephosphorylates and inactivates the 
death receptor CD95 but subsequently also the proteins 
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PKN2, PI3K p85β, IκBα and Rho-GAP, and reduced 
PTPN13 expression in afatinib resistant H1975 cells 
correlated with elevated tyrosine phosphorylation of 
ERBB3 and SRC Y416. Nota bene: as previously shown 
neither knock down of CD95 nor expression of the caspase 
8 inhibitor c-FLIP-s reduced the lethality of [pemetrexed 
+ sorafenib + afatinib] (Figures 9A and 9B). Thus by 
reducing PTEN levels the plasma membrane localization 
of other phosphatases is also reduced leading to greater 
levels of tyrosine phosphorylation -dependent signaling, 
particularly through the PI3K pathway.
From multiplex assays on tumor material in Figure 
13B we discovered that [pemetrexed + sorafenib + 
afatinib] exposed tumors had activated their PI3K and 
NFκB pathways. The drug flavopiridol (Alvocidib) is 
recognized as a CDK7/9 inhibitor but is also a potent 
inhibitor of IKKα/β [37-40]. Copanlisib is a class I 
selective PI3K p110α/β/γ/δ inhibitor. H1975 tumor 
clones from animals previously treated with [pemetrexed 
+ sorafenib + afatinib] exhibited greater sensitivity to 
both flavopiridol and copanlisib as single agents than 
did control clones (Figure S6C). In combination, using 
flavopiridol at two orders lower than its patient plasma 
Cmax and using copanlisib at one order lower than its 
reported Cmax, we noted profound levels of preferential 
[pemetrexed + sorafenib + afatinib] exposed cell killing 
with the drug combination but not with the individual 
drugs. In agreement with this data, expression of dominant 
negative IκB S32A S36A combined with simultaneous 
knock down of PI3K p110α/β synergized to kill tumor 
clones previously exposed to [pemetrexed + sorafenib + 
afatinib] (Figure S6D). Thus [flavopiridol + copanlisib] 
subverts secondary drug resistance mechanisms.
In conclusion, in this manuscript we have 
demonstrated that [pemetrexed + sorafenib] and 
[pemetrexed + sorafenib + afatinib] resistance mechanisms 
can be overcome in a rational unbiased fashion by use of 
multiplex antibody micro-array assays and pre-existing 
signaling pathway knowledge and analyses. The schematic 
in Figure S7 attempts to describe the multiple overlapping 
mechanisms by which [pemetrexed + sorafenib +/- 
afatinib] interact to kill tumor cells. Sorafenib inhibits the 
activities of multiple serine / threonine / tyrosine kinases 
as well as the chaperones GRP78, HSP90 and HSP70 (and 
other chaperones, e.g. HSP60, data not shown). Loss of 
GRP78 / HSP90 / HSP70 chaperone functions reduces 
gross protein translation through elevated ER stress eIF2α 
signaling leading to lower expression of growth factor 
receptors such as ERBB2 and mitochondrial protective 
proteins such as MCL-1, but also increases expression of 
the autophagosome regulatory proteins Beclin1, ATG5 
and LC3. Sorafenib, likely through HSP70 dysregulation 
and p38 MAPK inhibition, causes inactivation of the 
chaperone HSP27, which together with loss of GRP78, 
results in a destabilized PI3K signaling pathway, with 
lower levels of AKT and mTOR activity. Reduced 
AKT signaling de-represses the ER stress kinase PERK 
further facilitating the ER stress response caused by 
loss of GRP78 function. Reduced mTOR activity results 
in the dephosphorylation of ULK-1 at serine 757, and 
pemetrexed treatment through AMPK signaling increases 
ULK-1 serine 317 phosphorylation which collectively 
lead to a strong activation of ULK-1 kinase activity with 
the phosphorylation of ATG13, the gate-keeper protein 
for autophagosome formation, being strongly elevated. 
The phosphorylation of ATG13 is further enhanced due 
to reduced expression and co-localization of the serine / 
threonine protein phosphatase 1 with ATG16L1. Increased 
autophagosome / autolysosome flux leads to the release 
of cathepsins and calpains into the cytosol where they 
catalyze the cleavage of the toxic BH3 domain protein 
BID that occurs concomitantly with the ER stress -induced 
decline in MCL-1 and BCL-XL expression; and, loss of 
HSP90 and HSP70 function also enables the reduction 
in expression of these tumor cell protective proteins. The 
alterations in BID / MCL-1 / BCL-XL function result 
in the activation of BAX and BAK, and the release of 
apoptosis inducing factor into the cytosol. Additionally, 
because the function of HSP70 has been suppressed, AIF 
more readily translocates from the cytosol to the nucleus 
where it executes the tumor cell.
The addition of an ERBB1/2/4 inhibitor such 
as afatinib to [pemetrexed + sorafenib] enhanced the 
already present activated mechanisms outlined in the 
last paragraph, including enhanced down-regulation of 
chaperone expression resulting in enhanced ER stress 
signaling and also caused a more rapid inactivation of 
mTOR resulting in greater autophagosome formation. 
With regard to “toxic autophagy” in our pemetrexed 
studies, ourselves and others have found that estrogen-
dependent MCF7 cells, and many primary diagnosed 
breast cancers, have a haplotype insufficiency in Beclin1 
and thus are less effective at inducing autophagy than 
non-transformed mammary epithelial cells, although 
the clinical data from our phase I trial did not show low 
Beclin1 levels in any heavily pre-treated patient [41]. 
Hence this would suggest that loss of autophagy in the 
early development of breast cancer facilitates tumor 
formation. We previously discovered that fulvestrant 
resistant MCF7 cells expressed higher basal levels of 
Beclin1 and ATG5-ATG12, compared to parental MCF7 
cells arguing that this cell line in part maintains its 
viability in the face of estrogen deprivation by inducing 
a protective form of autophagy, yet this cell line also has 
much higher basal AKT / mTOR activity compared to 
control MCF7 cells which on paper would be expected 
to suppress the induction of autophagy, or autophagic 
flux, in the fulvestrant resistant cells. These findings also 
agree with other data showing that chloroquine, which 
inhibits autophagosome - lysosome fusion, can facilitate 
the anti-tumor effects of the anti-estrogen tamoxifen [42]. 
Previously we noted that the fulvestrant resistant MCF7 
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cells were more susceptible to [pemetrexed + sorafenib] 
killing which was dependent on the induction of a toxic 
form of autophagy [6, 43]. Thus collectively, we believe 
these findings further support the concept that it is the 
differential of the decline in AKT / mTOR signaling per 
se in real terms which plays the biggest role in the lethal 
autophagic processes being induced by the pemetrexed 
based drug combinations, rather than just the drugs simply 
“suppressing” pathway activities.
Additionally, however, by blocking the 
compensatory activation of ERBB1 caused by the two-
drug [pemetrexed + sorafenib] treatment, afatinib also acts 
to suppress the compensatory induction of anti-apoptotic 
SOD2 and the DNA repair enzyme XRCC1. Because 
of afatinib, [pemetrexed + sorafenib] does not increase 
SOD2 expression that in turn cannot act to suppress 
autophagosome formation and the generation of high 
levels of reactive oxygen species caused by mitochondrial 
dysfunction. Because XRCC1 induction is blocked by 
afatinib, DNA damage caused by pemetrexed persists, 
as judged by prolonged ATM activity, which can have 
multiple outcomes including: further NFκB activation; 
tumor cell death; genomic instability or senescence.
As [pemetrexed + sorafenib] has safely passed 
through phase I evaluation and into phase II specifically 
for triple negative mammary carcinoma (NCT02624700), 
the present findings strongly argue that a new phase I 
trial, in all solid tumor patients, combining [pemetrexed 




Pemetrexed was purchased from LC Laboratories 
(Woburn, MA). FTY720 was purchased from Cayman 
Chemical Inc., (Ann Arbor MI). Sorafenib tosylate and 
all ERBB receptor and kinase inhibitors were purchased 
from Selleckchem (Houston, TX). Trypsin-EDTA, 
DMEM, RPMI, penicillin-streptomycin were purchased 
from GIBCOBRL (GIBCOBRL Life Technologies, Grand 
Island, NY). Cells were purchased from the ATCC and 
were not further validated beyond that claimed by ATCC. 
Cells were re-purchased every ~6 months. The plasmid 
to express GRP78/BiP/HSPA5 was kindly provided 
to the Dent laboratory by Dr. A.S. Lee (University of 
Southern California, Los Angeles, CA); all other plasmids 
were purchased from Addgene. Commercially available 
validated short hairpin RNA molecules to knock down 
RNA / protein levels were from Qiagen (Valencia, CA) 
or were supplied by collaborators. Rabbit antiserum for 
mouse PERK phosphorylated at T799 was developed as 
described [44]. Reagents and performance of experimental 
procedures were described in refs: [12/13/17/18/21-
24/33/40].
Methods
Culture and in vitro exposure of cells to drugs
All cell lines were cultured at 37 oC (5% (v/v CO2) 
in vitro using RPMI supplemented with dialyzed 5% 
(v/v) fetal calf serum and 10% (v/v) Non-essential amino 
acids. Cells growing in “complete” fetal calf serum that 
contains thymidine were gradually weaned into dialyzed 
serum lacking thymidine over 2 weeks and were then 
used for experimental analyses for the following 3 weeks 
before discarding. Cells were re-isolated in thymidine-
less media as required. For short term cell killing assays, 
immunoblotting studies, cells were plated at a density 
of 3 x 103 per cm2 (~2 x 105 cells per well of a 12 well 
plate) and 48h after plating treated with various drugs, as 
indicated. In vitro pemetrexed, sorafenib and other drug 
treatments were generally from a 100 mM stock solution 
of each drug and the maximal concentration of Vehicle 
carrier (VEH; DMSO) in media was 0.02% (v/v). Cells 
were not cultured in reduced serum media during any 
study in this manuscript.
 Transfection of cells with siRNA or with plasmids
For plasmids
Cells were plated and 24h after plating, transfected. 
Plasmids expressing a specific mRNA (or siRNA) or 
appropriate vector control plasmid DNA was diluted in 
50μl serum-free and antibiotic-free medium (1 portion 
for each sample). Concurrently, 2μl Lipofectamine 
2000 (Invitrogen), was diluted into 50μl of serum-free 
and antibiotic-free medium (1 portion for each sample). 
Diluted DNA was added to the diluted Lipofectamine 
2000 for each sample and incubated at room temperature 
for 30 min. This mixture was added to each well / dish 
of cells containing 200μl serum-free and antibiotic-free 
medium for a total volume of 300 μl, and the cells were 
incubated for 4 h at 37 °C. An equal volume of 2x medium 
was then added to each well. Cells were incubated for 24h, 
then treated with drugs. 
Transfection for siRNA
Cells from a fresh culture growing in log phase as 
described above, and 24h after plating transfected. Prior 
to transfection, the medium was aspirated and serum-free 
medium was added to each plate. For transfection, 10 nM 
of the annealed siRNA, the positive sense control doubled 
stranded siRNA targeting GAPDH or the negative control 
(a “scrambled” sequence with no significant homology 
to any known gene sequences from mouse, rat or human 
cell lines) were used. Ten nM siRNA (scrambled or 
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experimental) was diluted in serum-free media. Four μl 
Hiperfect (Qiagen) was added to this mixture and the 
solution was mixed by pipetting up and down several 
times. This solution was incubated at room temp for 10 
min, then added drop-wise to each dish. The medium in 
each dish was swirled gently to mix, then incubated at 37 
oC for 2h. Serum-containing medium was added to each 
plate, and cells were incubated at 37 oC for 24h before 
then treated with drugs (0-24h). Additional immuno-
fluorescence / live-dead analyses were performed at the 
indicated time points.
Animal studies (breast cancer)
Athymic nude mice (~20 g) were injected with 1 
x 107 BT474 cells into their fourth mammary fat pad (8-
10 animals per treatment group; 6 groups; a total of 54 
mice +/- SEM). Alternatively, BALB/c immune competent 
mice (~20 g) were injected with 2 x 104 4T1 cells in their 
fourth mammary fat pad. Tumors were permitted to form 
in both animal models for 7 days with tumors at that 
time exhibiting a mean volume of ~25 mm3. For BT474, 
athymic mice were treated by oral gavage once every 
day for four days as indicated in the Figure and Figure 
Legend with vehicle (Cremophore); with pemetrexed 
(50 mg/kg) only on day 1; with sorafenib tosylate (25 
mg/kg) on days 1-4; with lapatinib (50 mg/kg) on days 
1-4; with vandetanib (25 mg/kg) on days 1-4. For studies 
with 4T1 cells, BALB/c mice were treated by oral gavage 
once every day for five days as indicated in the Figure 
and Figure Legend with vehicle (Cremophore) or with 
pemetrexed (50 mg/kg) only on day 1; with sorafenib 
tosylate (25 mg/kg) on days 1-5. After cessation of drug 
treatment tumors are again calipered and tumor volume 
was assessed up to 35 days later.
Animal studies (lung cancer)
Athymic nude mice (~20 g) were injected with 1 
x 107 H1975 cells into their rear flank (10 animals per 
treatment group; 4 groups; a total of 40 mice +/- SEM). 
Tumors were permitted to form for 7 days with tumors 
at that time exhibiting a mean volume of 25-50 mm3. 
Athymic mice were treated by oral gavage once every day 
QD for four days as indicated in the Figure and Figure 
Legend with vehicle (Cremophore); with pemetrexed (50 
mg/kg) only on day 1; with sorafenib tosylate (25 mg/kg) 
on days 1-5; with afatinib (10 mg/kg) on days 1-5. After 
cessation of drug treatment tumors are again calipered and 
tumor volume was assessed up to 20 days later. 
For studies to generate afatinib resistant H1975 cells, 
pre-existing tumors as above were treated with afatinib (50 
mg/kg) BID for 4 days. This reduced tumor volume of all 
clones to 0 for approximately 7 days after which tumors 
began to slowly re-grow. Recurrent tumors were isolated 
on Day 25, portions were snap-frozen or were digested to 
release individual tumor cells, and cells from each tumor 
clone maintained separately. Of significant note for clonal 
characterization, the isolated afatinib treated tumor cells 
were only growth inhibited by afatinib in vitro with daily 
supplementation at concentrations > > 2 µM, and as such 
these cells were routinely passaged in a pulsatile fashion 
between experiments in growth media containing only 1 
µM afatinib to maintain the phenotype but not to promote 
further selective pressure. 
Detection of cell viability, protein expression and 
protein phosphorylation by immuno-fluorescence 
using a Hermes WiScan machine
http://www.idea-bio.com\, Cells (4 x 103) are plated 
into each well of a 96 well plate, and cells permitted to 
attach and grow for the next 18h. Based on the experiment, 
after 18h, cells are then either genetically manipulated, 
or are treated with drugs. For genetic manipulation, 
cells are transfected with plasmids or siRNA molecules 
and incubated for an additional 24h. Cells are treated 
with vehicle control or with drugs at the indicated final 
concentrations, alone or in combination. Cells are then 
isolated for processing at various times following drug 
exposure. The 96 well plate is centrifuged / cyto-spun to 
associate dead cells (for live-dead assays) with the base 
of each well. For live dead assays, after centrifugation, 
the media is removed and cells treated with live-dead 
reagent (Thermo Fisher Scientific, Waltham MA) and 
after 10 min this is removed and the cells in each well are 
visualized in the Hermes instrument at 10X magnification. 
Green cells  =  viable; yellow/red cells  =  dying/dead. The 
numbers of viable and dead cells were counted manually 
from three images taken from each well combined with 
data from another two wells of separately treated cells 
(i.e. the data is the mean cell dead from 9 data points 
from three separate exposures). For immuno-fluorescence 
studies, after centrifugation, the media is removed and 
cells are fixed in place and permeabilized using ice cold 
PBS containing 0.4% paraformaldehyde and 0.5% Triton 
X-100. After 30 min the cells are washed three times with 
ice cold PBS and cells are pre-blocked with rat serum for 
3h. Cells are then incubated with a primary antibody to 
detect the expression/phosphorylation of a protein (usually 
at 1:100 dilution from a commercial vendor) overnight at 
37oC. Cells are washed three times with PBS followed 
by application of the secondary antibody containing an 
associated fluorescent red or green chemical tag. After 
3h of incubation the antibody is removed and the cells 
washed again. The cells are visualized at either 10X or 
60X in the Hermes machine for imaging assessments. 
All immunofluorescent images for each individual 
protein / phospho-protein are taken using the identical 
machine settings so that the levels of signal in each 
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image can be directly compared to the level of signal in 
the cells treated with drugs. Similarly, for presentation, 
the enhancement of image brightness/contrast using 
PhotoShop CS6 is simultaneously performed for each 
individual set of protein/phospho-protein to permit direct 
comparison of the image intensity between treatments. 
Antibodies used include: HSP90 (E289) (Cell Signaling); 
HSP90 (#2928) (Abcam); HSP90 (ab195575) Abcam; 
HSP90 3G3 (13495) (Abcam); GRP78 (50b12) (31772) 
(Cell Signaling); GRP78 (ab191023) Abcam; GRP78 
(ab103336) Abcam; GRP78 (N-20) (sc-1050) Santa Cruz; 
HSP27 (G31) (2402P) Cell Signaling); HSP27 [EP1724Y] 
(ab62339) Abcam; HSP27 (H-77) (sc-9012) Santa Cruz; 
HSP27 (LS-C31836) Lifespan science Corp. Other 
antibodies were as used in prior studies by the laboratory. 
All immunofluorescent images were initially visualized at 
75 dpi using an Odyssey infrared imager (Li-Cor, Lincoln, 
NE), then processed at 9999 dpi using Adobe Photoshop 
CS6. For presentation, immunoblots were digitally 
assessed using the provided Odyssey imager software. 
Images have their color removed and labeled figures 
generated in Microsoft PowerPoint.
Multiplex assays for cytokine expression
A Bio-Rad MAGPIX instrument with associated 
software was purchased from Bio-Rad. The following 
Bio-Plex assay plates were used in our assays of mouse 
plasma: PRO Mouse Cyto 23-PLEX (M60009RDPD); 
PRO TGF-B 3-PLEX (171W4001M); PRO Mouse Cyto 
Basic FGF set (171G6002M); Mouse Cyto STD GRP II 
9-PLEX (171I60001); Mouse Cyto LIF set (171G6003M); 
Mouse Cyto PDGF-BB set (171G6007M); Mouse Cyto 
VEGF set (171G6008M). Mouse plasma was assayed 
according to the instructions provided by Bio-Rad and 
with Bio-Rad technical assistance.
Isolation of GST-NH2 terminal HSP90 from 
bacteria and the measurement of its ATPase 
activity
E. coli BL21 [F-, ompT, hsdS (rB , mB ), gal] were 
transformed with a plasmid to express a fusion protein of 
the NH2-terminal portion of HSP90 fused to glutathione-
S-transferase (GST) (purchased from Addgene). Bacteria 
were grown at 24 oC with shaking until the A600 reached 
0.6. IPTG was added to a final concentration of 0.1 mM 
and the incubation continued for an additional 6 hours. 
Bacteria were recovered by centrifugation and stored on 
ice. The cell pellet was resuspended in 50 µl of ice-cold 
1X PBS per ml of culture. The re-suspended cells were 
mechanically disrupted using a probe sonicator, on ice, 
in short 5 second bursts. Triton X-100 was added to a 
final concentration of 1% (v/v) followed by 30 minutes 
of gentle shaking to aid in solubilization of the fusion 
protein. Bacterial debris and denatured proteins were 
removed by centrifugation at 15,000 x g for 20 min at 4 
oC. The supernatant was removed and immediately mixed 
with pre-equilibrated Glutathione Sepharose 4B (2 ml of 
a 50% Sepharose slurry is mixed with 100 ml of clarified 
bacterial sonicate. The Sepharose slurry is gently rotated in 
a cold room for 30 min. The slurry mixture is centrifuged 
(10,000 x g for 10 min) and the supernatant discarded. The 
Glutathione Sepharose is washed with 10 bead volumes of 
1X PBS. The Sepharose slurry is centrifuged (5,000 x g, 5 
min), and the supernatant discarded. The Sepharose beads 
are washed three times. Chaperone ATPase activity using 
the ATPlite 1step kit (PerkinElmer) was determined using 
GST-NH2 terminal HSP90 still linked to the Glutathione 
Sepharose 4B beads. The Sepharose beads are equilibrated 
in the reaction buffer provided by the manufacturer for 
30 min with gentle mixing, and the beads recovered by 
centrifugation. The beads are then resuspended 1:1 with 
reaction buffer. To each well of a 96 well plate is added 
50 µl of bead slurry and 50 µl of substrate buffer solution 
containing vehicle control or drug to achieve the desired 
final concentration. The reactions are started using a multi-
channel pipette delivering 50 µl of reconstituted reagent to 
each well. The plate is placed in foil in an orbital shaker 
at 37 oC for 15 min. The plate is removed; centrifuged 
to remove floating Sepharose beads; and 100 µl of the 
supernatant from each well placed into a new well in 
another 96 well plate. The light emitted from each well 
/ treatment condition is quantified using a Vector 3 plate 
reader (n = 3 of three studies +/- SEM).
Data analysis
Comparison of the effects of various treatments was 
performed using one-way analysis of variance and a two 
tailed Student’s t-test. Statistical examination of in vivo 
animal survival data utilized log rank statistical analyses 
between the different treatment groups. Differences with a 
p-value of < 0.05 were considered statistically significant. 
Experiments shown are the means of multiple individual 
points from multiple experiments (± SEM). 
Abbreviations
ERK: extracellular regulated kinase; PI3K: 
phosphatidyl inositol 3 kinase; ca: constitutively 
active; dn: dominant negative; PTX: pemetrexed; ER: 
endoplasmic reticulum; mTOR: mammalian target of 
rapamycin; MAPK: mitogen activated protein kinase; 
PTEN: phosphatase and tensin homologue on chromosome 
ten; ROS: reactive oxygen species; CMV: empty vector 
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